安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- ADSTILADRIN® (nadofaragene firadenovec-vncg) | For HCP
ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors
- ADSTILADRIN® (nadofaragene firadenovec-vncg) | NMIBC Treatment
ADSTILADRIN is the first and only FDA-approved gene therapy for treating adult patients with high-risk BCG-unresponsive NMIBC See Important Safety Info
- Adstiladrin: Uses, Dosage, Side Effects Warnings - Drugs. com
Adstiladrin is used to treat adult patients with high-risk, non-muscle invasive bladder cancer (NMIBC) that hasn't responded to the standard treatment, Bacillus Calmette-Guérin (BCG)
- Package Insert - ADSTILADRIN
ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy designed to deliver a copy of a gene encoding a human interferon-alfa 2b (IFNα2b) to the bladder urothelium
- Ferring Announces Update to NCCN Guidelines Expanding Category 2A . . .
ADSTILADRIN is an FDA-approved non-replicating intravesical gene-therapy for the treatment of adult patients with high-risk BCG-unresponsive NMIBC CIS with or without papillary tumors (±Ta T1), and is dosed once every three months
- Nadofaragene firadenovec - Wikipedia
Nadofaragene firadenovec, sold under the brand name Adstiladrin, is a gene therapy for the treatment of bladder cancer [1][3][4] It is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy
- More about ADSTILADRIN® – Bladder Cancer Advocacy Network
ADSTILADRIN is a localized gene therapy designed to help the immune system fight NMIBC directly within the bladder Administered once every 3 months, it works as a monotherapy, meaning it does not require combination with other medications to be effective
- Pharmacy Focus: Adstiladrin® A New Gene Therapy for a Specific . . . - HMIG
A gene therapy called Adstiladrin was approved December 16, 2022, for adult patients with a specific type of bladder cancer: high-risk bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors
|
|
|